摘要
以免疫检查点抑制剂为首的免疫治疗已成为黑素瘤的一线标准治疗手段,而程序性死亡因子1(programmed cell death-1,PD-1)抑制剂与细胞毒T淋巴细胞相关抗原4(cytotoxic T-lymphocyte-associated antigen-4,CTLA-4)抑制剂的联合应用,即免疫联合治疗进一步提高了药物的抗肿瘤效应,改善了患者的应答率,延长了患者的生存时间,因而成为黑素瘤治疗的新方向。与此同时,免疫联合治疗在其他多种肿瘤中的抗肿瘤效应也令人鼓舞。免疫联合治疗为患者提供了新的治疗选择,但同时也有诸多问题需要深入探讨。为使患者得到最大获益,如何优化联合治疗模式、如何选择合适的治疗人群、如何权衡患者风险获益等,都需要通过开展更多的大型临床研究予以解答。
Immunotherapy, primarily headed by immune checkpoint inhibitors, has become a standard, first-line therapeutic methodin treatment for patients with melanoma. Combination immunotherapy, that is the combination of programmed cell death-1 （PD-1） inhibitor and cytotoxic T-lymphocyte-associated antigen-4 （CTLA-4） inhibitor, further enhanced the anti-tumor efficacy, improved the objective response rate, and extended both the overall and progression- free survival of patients in the past years. Therefore, combination immunotherapy has also become a new direction for the treatment of melanoma. Meanwhile, the anti-tumor effects and clinical outcomes of combination immunotherapy in other types of tumors are also encouraging. Combination immunotherapy offers a new treatment option for patients, but there are still many issues that need to be further discussed. In order to maximize the benefit of patients, more large-scale clinical researches are needed to answer the questions which may strongly affect the clinical decisions, such as, how to optimize the regimens of combination therapy, how to identify the appropriate treatment population, and how to balance the risk-benefit ratio of patients.
出处
《肿瘤》
CAS
CSCD
北大核心
2017年第4期419-426,共8页
Tumor
基金
北京市优秀人才培养资助青年拔尖个人项目(编号:2014000021223ZK26)~~
作者简介
Correspondence to： GUO Jun （郭军） E-mail： guoj307@126.com
